Skip to content

Myopia Control Using Bright Light Therapy, Myopic Defocus and Atropine

Effectiveness of Bright Light Therapy, Myopic Defocus, Atropine and the Combinations for Controlling Myopic Eye Growth in Schoolchildren: A Randomized Control Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04923841
Enrollment
577
Registered
2021-06-11
Start date
2021-09-09
Completion date
2026-03-17
Last updated
2026-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Keywords

Myopia control, Bright light, Myopic defocus, Atropine

Brief summary

The purpose of the study is to investigate the effect of bright light therapy, myopic defocus, atropine and the combination in myopia control in schoolchildren.

Detailed description

The present study is a multi-arm randomised clinical trial with a 24-month duration. Subjects will be healthy Hong Kong Chinese schoolchildren with low to moderate myopia. The aims are to determine the clinical effectiveness of bright light therapy on inhibiting myopia progression in schoolchildren, and to determine whether combination therapy using bright light therapy (BLT) and myopic defocus is more effective than monotherapy. Study population Seven hundred and sixty Hong Kong Chinese children (152 in each) of A. Control group, B. BLT only group, C. BLT and Defocus Incorporated Multiple Segments (DIMS) group, D. BLT and atropine 0.01% group) and E. Atropine 0.01% group aged 7-12 years old will be recruited. They must not have had prior or current myopia control treatment, have no ocular or systemic diseases/abnormalities that affect visual function, refractive development or spectacle lens wear, and no previous intraocular or corneal surgery. They must not have allergy to atropine. The eligible subjects will be randomly assigned into one of the four groups. Their cycloplegic refraction and axial length will be monitored every six months for 2 years. The changes in refractive errors and axial length between groups will be compared.

Interventions

OTHERHigh intensity light box for bright light therapy and single vision spectacle lenses

High intensity light box for bright light therapy and single vision spectacle lenses

OTHERHigh intensity light box for bright light therapy and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses

High intensity light box for bright light therapy and Defocus Incorporated Multiple Segments (DIMS) spectacle lenses

OTHERHigh intensity light box for bright light therapy and atropine 0.01% eye drop and and single vision spectacle lenses

High intensity light box for bright light therapy and atropine 0.01% eye drop and and single vision spectacle lenses

OTHERAtropine 0.01% eye drop and and single vision spectacle lenses

Atropine 0.01% eye drop and and single vision spectacle lenses

Sponsors

The Hong Kong Polytechnic University
Lead SponsorOTHER
The University of Hong Kong
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
7 Years to 12 Years
Healthy volunteers
Yes

Inclusion criteria

* Myopia of at least -0.75D (spherical equivalent) in both eyes * Age at enrolment: 7-12 year; Hong Kong Chinese * Astigmatism and anisometropia: 1.50D or less * Spectacle corrected monocular visual acuity (VA): 0.0 logMAR or better * Parents' understanding and acceptance of random allocation of grouping and masking * Able to wear the prescribed spectacle, put on eye drop and undergo light therapy daily.

Exclusion criteria

* Eye disease or binocular vision problems (e.g., strabismus, amblyopia, oculomotor nerve palsies, corneal disease, etc.) * Previous intraocular or corneal surgery * Systemic disease that may affect vision, vision development (e.g. endocrine, cardiac and respiratory diseases, diabetes, Down syndrome, etc.) * Allergy to atropine * Previous gas permeable, soft bifocal, or orthokeratology contact lens wear or bifocal/PAL/specific myopic control spectacle wear or use of atropine or pirenzepine (longer than 1 month of wear) * Previous or current participation in myopia control studies

Design outcomes

Primary

MeasureTime frameDescription
Cycloplegic Refraction Change in spherical equivalent refraction (SER)Baseline and 2 yearsChange in cycloplegic SER (in diopter) will be measured using an open field autorefractor

Secondary

MeasureTime frameDescription
Axial lengthBaseline and 2 yearsAxial length (mm) will be measured after cycloplegia using a non-contact optical biometer

Countries

Hong Kong

Contacts

PRINCIPAL_INVESTIGATORChi Ho To, PhD

School of Optometry, The Hong Kong Polytechnic University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 13, 2026